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Summary We describe the application of a simple, rapid, semi-automated assay to the sensitivity testing of
cytotoxic drugs in 23 patients with acute myeloid leukaemia (AML). The survival of blast cells from the bone
marrow was measured by the MTT assay after 48h continuous exposure to drugs both singly and in
combination. There was a linear relationship between the number of leukaemic ceils and the optical density of
the formazan produced. The assay demonstrated a variation in drug sensitivity between patients. The
technique was reproducible and there was no significant difference in response between blast cells obtained
from bone marrow or from peripheral blood. Preliminary results show a correlation between in vitro and in
vivo data. The test can be repeated throughout the course of the disease to help identify any change in
tumour sensitivity. This technique appears to give useful information to assist in the management of acute
myeloid leukaemia.
Cytotoxic drug therapy remains the prime method of treat-
ment in acute myeloid leukaemia. One of the recognised
limitations of this therapy, however, is the inability to
predict tumour sensitivity in individual patients. Most atten-
tion in the field of haematological malignancies has focused
on the clonogenic assay (Marie et al., 1987), dye exclusion
assays (Weisenthal et al., 1986; Bird et al., 1988) and
radioactive precursor incorporation (Schwarzmeier et al.,
1984; Raza et al., 1987). The advantages and disadvantages
of these methods are well documented (Hill, 1983;
Wiesenthal & Lippman, 1985). A simple rapid chemosensi-
tivity test suitable for automation is what is required for
routine use. The clonogenic assay is long-term, effectively
measuring the chemosensitivity of dividing cells only. Evi-
dence is emerging to suggest that non-clonogenic assays
which measure cell kill in the total blast cell population may
be equally valuable. The most promising of these, the dye
exclusion assay, shows a good correlation with the end-point
of the clonogenic assay (Weisenthal et al., 1983). However, it
is not an automated technique and is therefore time-
consuming and subject to observer error.
In 1983 Mosmann described a semi-automated coloro-
metric assay based on the premise that the mitochondria of
living cells reduce the tetrazolium salt MTT to formazan. A
modified form of this is currently being successfully applied
by the National Cancer Institute USA to the chemosensi-
tivity testing of new drugs on cell lines (Alley et al., 1988).
The technique has been adapted for chemosensitivity testing
of chronic (Twentyman et al., 1989) and acute (Pieters et al.,
1988) lymphatic leukaemia cells. Results compared favour-
ably to those using the differential staining cytotoxicity
(DiSC) assay, a dye exclusion technique (Pieters et al., 1989).
It is important to validate this assay for each cell type,
and consequently we describe its application to the chemo-
sensitivity testing of blast cells from the bone marrow of
patients with acute myeloid leukaemia. These patients have a
poor prognosis even in those who achieve remission. A
simple in vitro method aiding initial selection of drugs both
singly and in combination and permitting retesting through-
out remission induction and on relapse would be a thera-
peutic advance.
Methods
Patients
Twenty-three patients have been tested, 18 with de novo
AML and five with chronic myeloid leukaemia in blast crisis.
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Thirteen patients were assayed both on presentation and
throughout the course of the disease, two after remission was
already established, three after relapse and the remaining five
patients tested initially had no follow-up as they did not
survive beyond the first course of treatment.
Preparation of cells
Bone marrow (5ml) was collected into 1 ml citrate phosphate
dextrose and tested within 48 h. Peripheral blood was used in
some subsequent assays if the blast cell numbers in the
circulation were sufficiently high. The mononuclear cells
were harvested using lymphocyte separation medium (Flow
Laboratories, Rickmansworth). All samples contained
>80% viable cells as checked by trypan blue dye exclusion.
The morphology of the sample was assessed on a cytospin
preparation using May-Grunwald-Giemsa stain.
Drug exposure
Drugs tested were doxorubicin, cytosine arabinoside, 6-
thioguanine, mitoxantrone, daunorubicin, etoposide and vin-
cristine. Stock solutions of 100pgml- were prepared in
normal saline and stored in aliquots at -20°C. Four
dilutions of each drug were made in RPMI 1640 plus 10%
fetal calf serum, 25 IUml-1 penicillin and 25 ugml-1
streptomycin. One hundred pl of double strength drug
dilution was placed in the appropriate well of a sterile flat
bottomed microtitre plate and 100p1 of a 1 x 106 cells ml-1
suspensien, also in RPMI, was added throughout giving
final drug concentrations in the therapeutically relevant
range (Metcalfe, 1983). If a combination of drugs was to be
tested equal quantities of each constituent were added to
give an appropriate total drug concentration, 100p1 of which
were added to the wells. Two hundred pl of complete
medium only was used as a blank and controls without drug
were interspersed throughout the plate. Each test was set up
in quadruplicate. The plate was then incubated in a humidi-
fied atmosphere for 2, 3, 4 or 7 days at 37°C in 5% CO2.
Cells were continuously exposed to the drugs throughout this
period.
MTT assay
The plate was inverted followed by a rapid flick to remove
the medium plus any drug (Denziot & Lang, 1986). Since the
cells had settled to the base of the well few were lost by this
procedure (10+7%). This was an improvement on the
number removed by needle aspiration (30+7%). Both tech-
niques resulted in 15-20,ul1 of medium remaining in the wells.
The simple flick-off method was therefore used. Fifty pl of
2mgml-1 MTT (Sigma Chemical Co. Ltd, Poole) in Hank's
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balanced salt solution (HBSS) without phenol red was added
to every well and the plate reincubated at 37°C in 5% CO2
for a further 4h. The formazan crystals formed were dis-
solved in 100p1 acid/alcohol (0.04NHCl in isopropanol) or
DMSO for comparative experiments by mixing on a micro-
shaker (Dynatech Labs, Ltd, Billingshurst) for 10min. The
plate was then read on a Dynatech microplate reader
MR600 at 570nm. The number of live cells per well was
calculated as a percentage of the control so measuring cell
survival after drug exposure. A dose-response curve was
plotted for each drug. In order to compare the results of the
assay with the clinical response to the drug, patients were
identified as sensitive (cell survival <30% at 1 gml-1) or
resistant (>30%) to the agents tested (Bird et al., 1988).
shown for comparison. The formazan crystals dissolved
easily in both acid/alcohol and DMSO after 10min on the
microshaker. As most of the medium was removed before
the addition of MTT we did not have any interference from
protein precipitation when using acid/alcohol. We did, how-
ever, experience some difficulty with foaming when using
DMSO (also reported by Pieters et al., 1988) and therefore
chose acid/alcohol for our procedure.
MTT concentration and incubation time Figure 2 shows the
effect of increasing both the concentration of MTT and the
incubation time. As 100pg MTT and 4h incubation gave the
greatest formazan production, this became our standard
procedure.
Assessment of clinical progress
The clinical progress of the disease was assessed by the
induction of complete or partial remission (Rees et al., 1986)
and by the reduction in peripheral blood blast cell counts
during the 48h following cytotoxic administration. The
differential white blood cell counts were performed by an
independent observer.
The statistical analysis was carried out using ANOVA to
compare the drug effects between patients. Linear regression
with correlation coefficient was used when comparing cell
numbers against formazan production and in vitro/in vivo
effects.
Results
Appraisal of method
Morphology and behaviour of blasts in short-term culture
The cell suspensions from patients on presentation or in
relapse contained 90+11% blasts. Those from patients
undergoing subsequent assays during or after treatment,
however, contained increasing numbers of normal cells.
Control cells remained viable throughout the 48h of the
assay as measured both by the amount of formazan pro-
duced and their ability to exclude trypan blue. A small
proportion of dividing cells were seen in mitosis in cytospin
preparations of control samples. Similar results were
obtained with fresh cells and samples stored for 48 h at 4°C.
Solvents There is some controversy over the best solvent to
solubilise the formazan crystals formed (Twentyman &
Luscombe, 1987; Carmichael et al., 1987). We tried both
acid/alcohol and DMSO to dissolve formazan generated
according to our methodology. Figure 1 shows there was no
difference in their absorbence spectrum in our system. As
there is some residual unconverted MTT in the wells, the
spectrum of 2mg MTT ml-1 HBSS without phenol red is
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Cell numbers versus formazan production The relationship
between the number of cells per well and the OD of the
formazan produced is shown in Figure 3. It is linear up to
4 x 105 cells per well. The amount offormazan produced by a
given number of cells varied between patients. The mean OD
at day 2 for 27 samples plated at 1 x 105 cells per well was
0.45+0.17, range 0.245-1.098.
Assay duration The effect of 2, 3, 4 and 7 day drug
exposure was tested in four patients. The experimental error
increased with time. The viability of control cells had halved
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Figure 2 Effect of MTT concentration on the formazan produc-
tion in AML blast c ells at h (), 2h (), 3h (O) and 4h ().
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Figure 2 Effect of MTT concentration on the formazan produc-
tion in AML blast cells at Ilh (A&), 2h (L9), 3h (0) and 4h (0).
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Figure 1 Absorbence of MTT formazan solutions in acid/
alcohol (0) and in DMSO (A); MTT solution alone (-).
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Figure 3 The relationship between the number of cells plated
and the optical density of the formazan produced in three
patients (O r=0.98, A r=0.97 and * r=0.98 respectively).208 J.M. SARGENT & C.G. TAYLOR
Table I Reproducibility of samples from four patients,
per cent survival (s.e.m.) at 1#gml-n of drug
Patient Drug Assay I Assay 2
A.K. mit 23(1) 19(2)
cer 20(3) 23(2)
L.G. mit 7(2) 10(1)
cer 4(1) 6(1)
I.B. adr 43(4) 39(3)
araC 24(2) 36(5)
F.B. adr 67(3) 66(3)
araC 64(3) 66(3)
6TG 101(2) 97(3)
mit, mitoxantrone; cer, daunorubicin; adr, doxorubicin;
araC, cytosine arabinoside; 6TG, 6-thioguanine.
by day 4 in two patients. These results concur with the
findings of Pieters et al. (1988). Incubation for longer than 2
days did not change the predicted sensitivity. A 48h drug
exposure was therefore chosen.
Reproducibility The repeatability of this assay in four
patients is indicated in Table I. There was no significant
difference (P>0.05) between the cell survival after drug
exposure using the same cells on two separate occasions.
Blasts from bone marrow versus blasts from peripheral blood
Figure 4 shows there is no significant difference in the
behaviour of blasts from bone marrow and those from
peripheral blood after exposure to 6-thioguanine, the combi-
nation of doxorubicin, cytosine arabinoside and 6-
thioguanine (DAT) and mitoxantrone. The 'peripheral blood
sample was taken 1 week after the bone marrow sample
without the patient receiving any intermediate treatment.
Leukaemic blasts from bone marrow and peripheral blood
also behave similarly in the DiSC assay (Bird et al., 1986).
Variation in drug sensitivity The dose-response curves for
patients with AML after exposure to doxorubicin, cytosine
arabinoside, 6-thioguanine and mitoxantrone are shown in
Figure 5, confirming significant variation between patients.
Clinical significance
In vitro-in vivo correlation Table II shows the in vitro drug
effect against the clinical outcome in 21 cases. The compari-
son was made with the same drug or combination tested in
vivo and in vitro or, if the appropriate combination was not
tested in vitro, the most effective single agent. The results
corresponded well, with two exceptions. In 10 cases the cells
were sensitive to the drugs in vitro and the patients attained
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Figure 5 Dose response to (a) doxorubicin n= 15, (b) cytosine
arabinoside n= 16, (c) 6-thioguanine n= 13 and (d) mitoxantrone
n= 10. The dotted lines represent samples taken from the two
patients already in remission.
remission on this treatment. In nine cases the assay demon-
strated resistance in vitro and the patients failed to gain
remission.
Figure 6 shows the significant correlation (P<0.0001)
between the blasts killed in vitro and in vivo by the same
drug or combination as above. The in vitro effect was
measured as the percentage drop in cell numbers after
exposure to 1 gml-1 of single drug or 3 gml-I total drug
concentration if in combination. This was compared to the
percentage fall in peripheral blood blast cells during the 48h
following cytotoxic administration. The correlation is still
significant (P=0.003), with subsequent assays carried out
during remission induction despite increasing numbers of
normal cells.
Sequential assays One patient was tested in vitro on six
separate occasions (Figure 7). While his cells remained
consistently resistant to cytosine arabinoside, the last two
assays showed that doxorubicin no longer had an effect. We
noted the post-treatment increase in sensitivity to doxo-
rubicin in the fourth assay which supports the theory
proposed by Selby et al. (1983) that tumour debulking may
recruit a population of cells which divide actively and
therefore are more sensitive to chemotherapy.
Discussion
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Figure 4 Comparison of the response to 6-thioguanine
(squares), combination of doxorubicin, cytosine arabinoside and
6-thioguanine (circles) and mitoxantrone (triangles) for bone
marrow (solid symbols) and peripheral blood (open symbols)
from the same patient.
There is growing evidence to support the value of non-clono-
genic assays. The drug sensitivity of a sample representative
of the entire tumour cell population may provide a better
prediction of the tumour response and behaviour in vivo.
Cytotoxic drugs are not only effective against dividing cells
but alter essential cellular function in the resting phase of the
cell cycle (Weisenthal & Lippman, 1985). This damage is not
measured in clonogenic assays. Most non-clonogenic
methods, however, have proved relatively time-consuming.
We have found the MTT assay to be simple, rapid, inexpen-
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Table II Comparison of MTT assay with clinical response
Previous In vitro/in vivo
Patient drugs Results in vitro Response in vivo comparison
1 None S: adr, araC; R: 6TG, vin PR: 6TG R/R
2 None R: araC, 6TG PR: araC, 6TG R/R
3a None S: adr, vin; R: araC, 6TG CR: adr, araC, 6TG S/S
3b R: adr, araC, 6TG, vin PR: adr, araC, 6TG, vin, cy R/R
3c S: mit; R: adr, araC, 6TG, CR: mit, cy S/S
vin
4 araC, 6TG R: adr, araC PR: adr, araC, 6TG R/R
5 bus S: adr; R: araC, 6TG PR: araC, 6TG R/R
6 None S: adr, araC, 6TG PR: araC, 6TG S/R
7 None S: DAT, adr, araC, mit CR: adr, araC, 6TG S/S
R: 6TG, vin
8 None S: DAT, adr; R: araC, 6TG CR: cer, araC, etop S/Sa
9 None S: DAT, ADE, adr, cer, CR: cer, araC, 6TG S/S
araC; R: etop, 6TG
10 bus S: adr, mit, DAT; PR: adr, araC, 6TG S/R
R: araC, 6TG
1 la None S: adr, araC; R: 6TG CR: adr, araC, 6TG S/S
1 lb S: MAT, mit; R: DAT CR: mit, araC, 6TG S/S
adr, araC, 6TG
12 6TG R: adr, araC, 6TG PR: 6TG R/R
13 6TG, vin S: adr; R: araC, 6TG PR: 6TG R/R
14 None R: DAT, adr, PR: araC R/R
araC, 6TG
15 None S: DAT, adr, araC, MAT CR: adr, araC, 6TG S/S
mit; R: 6TG, vin
16 None S: DAT, adr, mit, vin CR: cer, araC, etop S/S"
R: araC, 6TG
17 None R: ADE PR: araC, cer, etop R/R
18 None S: DAT, adr, mit; CR: adr, araC, 6TG S/S
R: araC, 6TG
R, resistant; S, sensitive; CR, complete remission; PR, partial remission; adr, doxorubicin; araC, cytosine arabinoside;
6TG, 6 thioguanine; mit, mitoxantrone; cer, daunorubicin; etop, etoposide; vin, vincristine; cy, cyclophosphamide; bus,
busulphan; DAT, combination of doxorubicin, cytosine arabinoside and 6-thioguanine tested in vitro; MAT, combination
of mitoxantrone, cytosine arabinoside and 6-thioguanine tested in vitro; ADE, combination of cytosine arabinoside,
daunorubicin and etoposide tested in vitro.
aDoxorubicin tested in vitro and compared to the effect of its analogue daunorubicin in vivo.
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Figure 6 In vitro-in vivo correlation (r=0.83, P<0.0001). Initial
assay followed by first treatment (0), subsequent assays as the
patients achieve remission (O r=0.72, P=0.003).
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sive and repeatable. Semi-automation has enabled the testing
of a range of drugs singly and in combination. The drug
sensitivity of every tumour can be assessed before each
course of therapy.
We were impressed by the reproducibility of the MTT
assay and the similar behaviour of blasts from both bone
marrow and peripheral blood. Although all samples tested
were taken from patients with acute myeloid leukaemia, the
blast cell drug sensitivity between these patients was remark-
ably varied. This information could enable the selection of
Figure 7 Sequential assays carried out over a period of a year
from a patient with AML after exposure to 1 #gml-1 doxo-
rubicin (0), cytosine arabinoside (O) and vincristine (E]).
Details of chemotherapy are also shown. DAT, doxorubicin,
cytosine arabinoside and 6-thioguanine; V, vincristine; C, cyclo-
phosphamide; a, asparaginase; M, mitoxantrone.
effective drugs, so sparing the patient toxicity from inappro-
priate agents.
The in vitro results must relate to the in vivo drug effects.
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The fall in peripheral blood blast cell count following drug
administration was very similar to that in the in vitro assay.
This may be useful as an early indication of prediction
sensitivity. However, for this test to have clinical relevance
the in vitro results must predict the tumour response. Our
preliminary results are encouraging. The attainment of
remission correlated with the results of the assay in 19 out of
the 21 cases we have data for so far. In two cases we
predicted that a drug would be useful when the patient did
not respond. These patients had end-stage disease at the time
of testing. We had no false negative results. The overall low
remission rate in these patients reflects the poor prognosis of
their advanced disease, only 13 patients being tested before
first remission.
A change in drug sensitivity may be observed by testing
sequentially. The ability to detect this is important in the
clinical situation and offers the possibility of selecting second
line agents when conventional regimes have failed. Figure 7
shows doxorubicin becoming less effective. During this time
the patient relapsed and failed to gain a second remission
with the original treatment. The drugs were changed and a
second remission was induced using mitoxantrone, which
also showed the greatest cell kill in the MTT assay. A
similar pattern has since been observed in a second patient.
In conclusion, these preliminary results indicate that the
MTT assay is a suitable technique for routine application to
the chemosensitivity of blast cells from patients with AML.
In future it may be possible to select treatment for individual
patients on the basis of the rapidly acquired results of this
assay. An early indication of tumour sensitivity could by
implication improve early remission rates leading to a better
prognosis.
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